A newly accepted study in BMC Chemistry adds useful evidence to one of the central questions in nicotine regulation: how does the chemical profile of oral nicotine pouches compare with established tobacco products?
The study, led by Simone Hadley and colleagues, measured 132 analytes across 11 commercially available oral nicotine pouches, alongside two Swedish snus products. The researchers also compared the results with historical emissions data from a reference cigarette. Their analysis found substantially fewer quantifiable compounds in nicotine pouches than in snus and, for most of the toxicants that could be compared, substantially lower levels than those found in cigarette smoke.
These findings are relevant to discussions about relative risk. They need to be interpreted within clear limits.
Chemical analysis measures what is present in a product. It does not directly measure what happens to people who use it over many years. Nor can a single laboratory study establish the population-level health effects of nicotine pouches.
That distinction is important for regulators.
A Broad Look at Product Chemistry
One strength of the study is its scope.
Researchers tested for 132 substances across several chemical classes. These included tobacco-specific nitrosamines, polycyclic aromatic hydrocarbons, carbonyls, nicotine-related compounds and elements. Seventy of the 132 analytes were below quantifiable levels across all of the nicotine pouch and snus samples. Of the remaining compounds, 58 were quantifiable in at least one snus sample and 47 in at least one nicotine pouch.
Where compounds were measurable in both categories, the nicotine pouches generally contained lower quantities. The authors report that in most comparisons, measured analyte levels in the pouches were more than 90% lower than in the snus products.
The comparison with cigarette smoke was also striking.
Among 40 compounds found at lower levels in nicotine pouches than in the reference cigarette smoke data, 34 were more than 90% lower. For eight toxicants identified by the WHO Study Group on Tobacco Product Regulation as priorities for reduction, the measured levels in nicotine pouches were between 98.7% and 99.9% lower than in cigarette smoke.
This is consistent with an important feature of the product category: nicotine pouches contain no tobacco leaf and involve no combustion.
Why Combustion Matters
Cigarette smoking creates a particularly hazardous exposure because tobacco is burned and the resulting smoke is inhaled.
Nicotine pouches work differently. Nicotine is absorbed through the oral mucosa, without generating smoke. Removing combustion removes a major source of many toxicants associated with cigarette smoking.
The new study provides chemical evidence consistent with that distinction.
It also reports differences between tobacco-containing snus and tobacco-free nicotine pouches. This is relevant because the two oral products can appear similar in use while differing in composition. The researchers found more quantifiable analytes in the snus samples than in the nicotine pouches, although some compounds were detected in the pouches and individual results varied between products.
This does not establish that nicotine pouches are harmless.
It does reinforce why regulators should be careful about treating product categories as chemically equivalent simply because they contain nicotine.
Lower Toxicant Levels Are Relevant to Risk, but They Are Not the Same as Health Outcomes
This is where interpretation becomes particularly important.
A large reduction in measured toxicants is meaningful. Exposure to harmful chemicals is part of the pathway through which tobacco products cause disease, and comparative chemistry is therefore valuable when assessing the likely risk profile of different nicotine products.
Yet chemical measurements alone cannot tell us the magnitude of long-term health risk.
They do not establish rates of cardiovascular disease, cancer, oral disease or other clinical outcomes among long-term users. They also cannot fully capture how products are used in everyday life, how much nicotine individuals consume, whether people switch completely from cigarettes, or whether they continue using several products simultaneously.
The authors themselves frame their work as a chemical characterisation study. Its findings should be understood on those terms.
This matters because discussions about nicotine pouches can move too quickly in either direction. Finding toxicants in a product does not by itself establish that its risk approaches that of smoking. Finding substantially lower toxicant levels does not prove that long-term use is safe.
Good risk communication needs to leave room for both facts.
Some Compounds Were Still Detected
The detailed results also show why product standards remain important.
Although the overall toxicant profile was lower in the tested nicotine pouches, the study did not find an absence of potentially relevant compounds.
Across the full analysis, several classes of substances were quantifiable in at least some products, including nicotine-related alkaloids, elements, tobacco-specific nitrosamines, polycyclic aromatic hydrocarbons and carbonyls. Four analytes that were not quantifiable in the tested snus products were quantifiable in some nicotine pouches.
The comparison with cigarette smoke was not uniformly lower for every substance either. Nicotine-1′-oxide was the compound present at the highest relative level in the pouches compared with cigarette smoke.
These details should not be lost behind headline percentage reductions.
They point towards a practical regulatory question: if nicotine pouches are going to remain available to adult consumers, what manufacturing and toxicological standards should they be required to meet?
That is where analytical research can become particularly useful.
Product Standards Could Turn Chemistry Into Regulation
A regulatory framework can do more than establish whether nicotine pouches are permitted or prohibited.
It can define acceptable product characteristics.
Manufacturers can be required to disclose ingredients and provide toxicological data. Regulators can establish testing methods, manufacturing requirements and limits for contaminants or unwanted constituents where the evidence supports them. Market surveillance can then assess whether products continue to meet those requirements.
Chemical studies such as this one can help inform that process.
They can identify substances that should be monitored and reveal variation between products. Over time, evidence from independent laboratories and different manufacturers can help regulators determine which compounds warrant limits or routine disclosure.
This approach also allows standards to change as the evidence develops.
GINN has argued in its response to the European Commission’s review of tobacco rules that novel nicotine products require a framework capable of reflecting differences in their toxicological profiles rather than automatically applying rules developed for combustible tobacco.
The new study adds data relevant to that discussion.
Funding and Conflicts of Interest Need to Be Transparent
There is another important consideration.
The study was funded by British American Tobacco (Investments) Ltd. Five of the six authors were BAT employees at the time of the research. The remaining author is an independent consultant who provides scientific support to BAT. The paper also states that BAT wholly owns Nicoventures Trading Limited, which manufactures many of the products evaluated in the study.
That does not make the results invalid. It does mean the funding and competing interests should be stated clearly when the evidence is discussed.
The paper reports the use of standard and verified analytical methods, and publication in a scientific journal provides an avenue for scrutiny. Even so, replication by independent researchers would strengthen confidence in the findings, particularly given the commercial relationship between the study sponsor and several products tested.
Independent replication matters in all areas of regulatory science. Here, it is especially valuable.
A growing evidence base should include studies from academic laboratories, government agencies and industry researchers, with methods and conflicts disclosed so that results can be compared critically.
The Evidence Base Is Still Developing
The paper does not stand alone.
Its reference base includes previous research examining harmful and potentially harmful constituents in nicotine pouches, nicotine-related impurities, tobacco-specific nitrosamines and comparisons with smokeless tobacco and nicotine replacement products.
Taken together, this literature is beginning to provide a clearer picture of product chemistry.
The larger health evidence remains less mature.
Nicotine pouches are relatively recent products in many markets, which means decades of epidemiological data are unavailable. Questions around long-term oral effects, cardiovascular outcomes, dependence, patterns of dual use and population-level switching require continued investigation.
That uncertainty should be communicated accurately. It should also be placed in context.
Waiting for several decades of epidemiological evidence before acknowledging existing differences in toxicant exposure would provide regulators with an incomplete picture. Treating early chemical findings as definitive evidence of long-term safety would create the opposite problem.
Regulation has to work with the evidence available today while remaining capable of changing tomorrow.
What This Means for GINN
For GINN, the significance of the BMC Chemistry study lies less in any single percentage reduction than in what comparative toxicology can contribute to better nicotine regulation.
Products should be assessed according to their actual characteristics.
Where evidence shows substantial differences in toxicant profiles between combustible cigarettes, tobacco-containing oral products and tobacco-free nicotine pouches, those differences should be considered in regulatory decision-making. At the same time, lower toxicant levels should not become a substitute for long-term health research, surveillance or robust product standards.
This is where risk-proportionate regulation needs precision.
Youth access should remain tightly controlled. Marketing should be responsible and directed towards adults. Product composition should be subject to clear standards and testing. Regulators should continue monitoring health evidence as it develops.
For adults who smoke, however, accurate information about relative exposure also matters. Public-health communication becomes less useful when fundamentally different products are discussed as though their risks are interchangeable.
Looking Ahead
The Hadley et al. study provides a detailed chemical comparison and reports substantially lower levels of many measured toxicants in the nicotine pouches tested than in Swedish snus and cigarette smoke.
That is useful evidence.
It is not the final word on nicotine pouch safety.
Independent replication, longer-term clinical research and population surveillance are still needed. Future studies should also examine a wider range of manufacturers and products as the market evolves.
For regulators, however, uncertainty does not mean that all products must be treated as equivalent until every question has been answered.
The more constructive approach is to use comparative toxicology alongside clinical, behavioural and epidemiological evidence to build standards that reflect what is known, identify what remains uncertain and adjust as new evidence emerges.
Nicotine regulation will increasingly depend on this kind of distinction.
The question should not simply be whether a product contains nicotine. Regulators also need to understand what else it contains, how people are exposed to it, and how that exposure compares with the products it may replace.
That is where studies such as this can make a useful contribution to evidence-based nicotine policy.
Source:
https://link.springer.com/article/10.1186/s13065-026-01895-x
